Antiemesis

Authors:
David S. Ettinger
Search for other papers by David S. Ettinger in
Current site
Google Scholar
PubMed Close
 MD
,
Debra K. Armstrong
Search for other papers by Debra K. Armstrong in
Current site
Google Scholar
PubMed Close
 RN
,
Sally Barbour
Search for other papers by Sally Barbour in
Current site
Google Scholar
PubMed Close
 PharmD, BCOP
,
Michael J. Berger
Search for other papers by Michael J. Berger in
Current site
Google Scholar
PubMed Close
 PharmD, BCOP
,
Philip J. Bierman
Search for other papers by Philip J. Bierman in
Current site
Google Scholar
PubMed Close
 MD
,
Bob Bradbury
Search for other papers by Bob Bradbury in
Current site
Google Scholar
PubMed Close
 BCPS
,
Georgianna Ellis
Search for other papers by Georgianna Ellis in
Current site
Google Scholar
PubMed Close
 MD
,
Steve Kirkegaard
Search for other papers by Steve Kirkegaard in
Current site
Google Scholar
PubMed Close
 PharmD
,
Dwight D. Kloth
Search for other papers by Dwight D. Kloth in
Current site
Google Scholar
PubMed Close
 PharmD, FCCP, BCOP
,
Mark G. Kris
Search for other papers by Mark G. Kris in
Current site
Google Scholar
PubMed Close
 MD
,
Dean Lim
Search for other papers by Dean Lim in
Current site
Google Scholar
PubMed Close
 MD
,
Michael Anne Markiewicz
Search for other papers by Michael Anne Markiewicz in
Current site
Google Scholar
PubMed Close
 PharmD
,
Lida Nabati
Search for other papers by Lida Nabati in
Current site
Google Scholar
PubMed Close
 MD
,
Carli Nesheiwat
Search for other papers by Carli Nesheiwat in
Current site
Google Scholar
PubMed Close
 PharmD, BCOP
,
Hope S. Rugo
Search for other papers by Hope S. Rugo in
Current site
Google Scholar
PubMed Close
 MD
,
Steven M. Sorscher
Search for other papers by Steven M. Sorscher in
Current site
Google Scholar
PubMed Close
 MD
,
Lisa Stucky-Marshal
Search for other papers by Lisa Stucky-Marshal in
Current site
Google Scholar
PubMed Close
 RN, MS
,
Barbara Todaro
Search for other papers by Barbara Todaro in
Current site
Google Scholar
PubMed Close
 PharmD
, and
Susan Urba
Search for other papers by Susan Urba in
Current site
Google Scholar
PubMed Close
 MD
Volume/Issue:
Volume 7: Issue 5
Online Publication Date:
May 2009
DOI:
https://doi.org/10.6004/jnccn.2009.0039
Full access
  • Collapse
  • Expand
Print ISSN:
1540-1405
Online ISSN:
1540-1413
Publisher:
National Comprehensive Cancer Network
Cover Journal of the National Comprehensive Cancer Network
  • 1

    Laszlo J. Emesis as limiting toxicity in cancer chemotherapy. In: Laszlo J, ed. Antiemetics and Cancer Chemotherapy. Baltimore: Williams & Wilkins; 1983:1–5.

  • 2

    Ingle RJ, Burish TG, Wallston KA. Conditionability of cancer chemotherapy patients. Oncol Nurs Forum 1984;11:97–102.

  • 3

    Mitchell EP. Gastrointestinal toxicity of chemotherapeutic agents. Semin Oncol 1992;19:566–579.

  • 4

    Richardson JL, Marks G, Levine A. The influence of symptoms of disease and side effects of treatment on compliance with cancer therapy. J Clin Oncol 1988;5:1746–1752.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5

    Morran C, Smith DC, Anderson DA et al.. Incidence of nausea and vomiting with cytotoxic chemotherapy: a prospective randomized trial of antiemetics. Br Med J 1979;1:1323–1324.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6

    Jenns K. Importance of nausea. Cancer Nurs 1994;17:488–493.

  • 7

    Nesse RM, Carli T, Curtis GC et al.. Pretreatment nausea in cancer chemotherapy: a conditioned response? Psychosom Med 1980;42:33–36.

  • 8

    Wilcox PM, Fetting JH, Nettesheim KM et al.. Anticipatory vomiting in women receiving cyclophosphamide, methotrexate, and 5-FU (CMF) adjuvant chemotherapy for breast carcinoma. Cancer Treat Rep 1982;66:1601–1604.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9

    Carey MP, Burish TG. Anxiety as a predictor of behavioral therapy outcome for cancer chemotherapy patients. J Consult Clin Psychol 1985;53:860–865.

  • 10

    Morrow GR, Lindke J, Black PM. Predicting development of anticipatory nausea in cancer patients: prospective examination of eight clinical characteristics. J Pain Symptom Manag 1991;6:215–223.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11

    Hickok JT, Roscoe JA, Morrow GR et al.. 5-Hydroxytryptamine-receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomised controlled trial. Lancet Oncol 2005;6:765–772.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12

    Craig JB, Powell BL. The management of nausea and vomiting in clinical oncology. Am J Med Sci 1987;293:34–44.

  • 13

    Borison HL, Wang S. Physiology and pharmacology of vomiting. Pharmacol Rev 1953;5:193–230.

  • 14

    Siegel LJ, Longo DL. The control of chemotherapy-induced emesis. Ann Intern Med 1981;95:352–359.

  • 15

    Dodds LJ. The control of cancer chemotherapy-induced nausea and vomiting. J Clin Hosp Pharm 1985;10:143–166.

  • 16

    Kris MG, Gralla RJ, Clark RA et al.. Incidence, course and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol 1985;3:1379–1384.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17

    Roila F, Boschetti E, Tonato M et al.. Predictive factors of delayed emesis in cisplatin patients and anti-emetic activity and tolerability of metoclopramide or dexamethasone. Am J Clin Oncol 1991;14:238–242.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18

    Moher D, Arthur AZ, Peter JL. Anticipatory nausea and/or vomiting in chemotherapy patients. Cancer Treat Rev 1984;11:257–264.

  • 19

    Jacobsen PB, Redd WH. The development and management of chemotherapy-related anticipatory nausea and vomiting. Cancer Invest 1988;6:329–336.

  • 20

    Morrow GR. Clinical characteristics associated with the development of anticipatory nausea and vomiting in cancer patients undergoing chemotherapy treatment. J Clin Oncol 1984;2:1170–1176.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 21

    Harding RK, Young RW, Anno GH. Radiotherapy-induced emesis. In: Andrews PLR, Sanger GJ, eds. Emesis in Anti-Cancer Therapy. London: Chapman & Hall Medical; 1993:163–178.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 22

    Roila F, Hesketh PJ, Herrstedt J et al.. Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 2006;17:20–28.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 23

    Kris MG, Hesketh PJ, Somerfield MR et al.. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 2006;24:2932–2947.

  • 24

    Laszlo J. Treatment of nausea and vomiting caused by cancer chemotherapy. Cancer Treat Rev 1982;9:3–9.

  • 25

    Strum SB, McDermed JE, Pileggi J et al.. Intravenous metoclopramide: prevention of chemotherapy-induced nausea and vomiting. Cancer 1984;53:1432–1439.

  • 26

    Lindley CM, Bernard S, Fields SM. Incidence and duration of chemotherapy-induced nausea and vomiting in the outpatient oncology population. J Clin Oncol 1989;7:1142–1149.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 27

    Aapro MS. Methodological issues in anti-emetic studies. Invest New Drugs 1993;11:243–253.

  • 28

    Hesketh PJ, Kris MG, Grunberg SM et al.. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 1997;15:103–109.

  • 29

    Grunberg SM, Osoba D, Hesketh PJ et al.. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity–an update. Support Care Cancer 2005;13:80–84.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 30

    Koeller JM, Aapro MS, Gralla RJ et al.. Antiemetic guidelines: creating a more practical treatment approach. Support Care Cancer 2002;10:519–522.

  • 31

    Hesketh PJ, Gandara DR. Serotonin antagonists: a new class of antiemetic agents. J Natl Cancer Inst 1991;83:613–620.

  • 32

    Andrews PL, Bhandari P, Davey PT et al.. Are all 5-HT3 receptor antagonists the same? Eur J Cancer 1992;28A(Suppl 1):S2–6.

  • 33

    Grunberg SM, Koeller JM. Palonosetron: a unique 5-HT3-receptor antagonist for the prevention of chemotherapy-induced emesis. Expert Opin Pharmacother 2003;4:2297–2303.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 34

    Grunberg SM, Stevenson LL, Russell CA et al.. Dose-ranging phase I study of the serotonin antagonist GR 38032F for prevention of cisplatin-induced nausea and vomiting. J Clin Oncol 1989;7:1137–1141.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 35

    Chevallier B. Efficacy and safety of granisetron compared with high-dose metoclopramide plus dexamethasone in patients receiving high-dose cisplatin in a single-blind study. Eur J Cancer 1990;26:S33–36.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 36

    Cupissol DR, Serrou B, Caubel M. The efficacy of granisetron as prophylactic anti-emetic and intervention agent in high-dose cisplatin-induced emesis. Eur J Cancer 1990;26:S23–27.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 37

    DeMulder PHM, Seynaeve C, Vermorken JB et al.. Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. Ann Intern Med 1990;113:834–840.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 38

    Marty M. A comparative study of the use of granisetron, a selective 5-HT3 antagonist, versus a standard anti-emetic regimen of chlorpromazine plus dexamethasone in the treatment of cytostatic-induced emesis. Eur J Cancer 1990;26(Suppl 1):S28–32.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 39

    Marty M, Pouillart P, School S et al.. Comparison of the 5-hydroxytryptamine3 (serotonin) receptor antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med 1990;322:816–821.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 40

    Soukop M. A comparison of two dose levels of granisetron in patients receiving high-dose cisplatin. Eur J Cancer 1990;26(Suppl 1):S15–19.

  • 41

    Roila F, Tonato M, Cognetti F et al.. Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol 1991;9:675–678.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 42

    Fraschini G. Antiemetic activity of ondansetron in cancer patients receiving non-cisplatin chemotherapy. Semin Oncol 1992;19(4 Suppl 10):S41–47.

  • 43

    Kamanabrou D. Intravenous granisetron establishing the optimal dose. Eur J Cancer 1992;28A(Suppl 1):S6–11.

  • 44

    Sledge GW Jr, Einhorn L, Nagy C et al.. Phase III double-blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple-day cisplatin-based chemotherapy. Cancer 1992;70:2524–2528.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 45

    Chevallier B. The control of acute cisplatin-induced emesis—a comparative study of granisetron and combination regimen of high-dose metoclopramide and dexamethasone. Br J Cancer 1993;68:176–180.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 46

    Navari RM, Kaplan HG, Gralla RJ et al.. Efficacy and safety of granisetron, a selective 5-HT antagonist, in the prevention of nausea and vomiting induced by high dose cisplatin. J Clin Oncol 1994;12:2204–2210.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 47

    Riviere A. Dose-finding study of granisetron in patients receiving high-dose cisplatin chemotherapy. Br J Cancer 1994;69:967–971.

  • 48

    Eisenberg P, Figueroa-Vadillo J, Zamora R et al.. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer 2003;98:2473–2482.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 49

    Aapro MS. Palonosetron as an anti-emetic and anti-nausea agent in oncology. Ther Clin Risk Manag 2007;3:1009–1020.

  • 50

    Grunberg S, Gabrial N, Clark G. Phase III trial of transdermal granisetron patch (Sancuso) compared to oral granisetron (OG) for chemotherapy-induced nausea and vomiting (CINV) after multi-day moderately emetogenic (MEC) or highly emetogenic (HEC) chemotherapy [Abstract]. MASCC/ISOO 20th Anniversary International Symposium Supportive Care in Cancer; St. Gallen, Switzerland; June 27–30, 2007:687. Astract P-18.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 51

    Gralla R, Lichinitser M, Van Der Vegt S et al.. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003;14:1570–1577.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 52

    Bonneterre J, Hecquet B. Granisetron (IV) compared with ondansetron (IV plus oral) in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. A crossover study. Bull Cancer 1995;82:1038–1043.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 53

    Jantunen IT, Kataja VV, Johansson RT. Ondansetron and tropisetron with dexamethasone in the prophylaxis of acute nausea and vomiting induced by non-cisplatin-containing chemotherapy. Acta Oncol 1992;31:573–575.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 54

    Jantunen IT, Muhonen TT, Kataja VV et al.. 5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy—a randomised study. Eur J Cancer 1993;29A:1669–1672.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 55

    Martoni S, Angelelli B, Guaraldi M et al.. Granisetron (GRA) vs. ondansetron (OND) in the prevention of cisplatinum-induced emesis: an open randomized cross-over study. Am Soc Lin Oncol 1993;13:431.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 56

    Campora LE, Simoni C, Rosso R. [Tropisetron versus ondansetron in the prevention and control of emesis in patients undergoing chemotherapy with FAC/FEC for metastatic or surgically treated breast carcinoma]. Minerva Med 1994;85:25–31 [in Italian].

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 57

    Gebbia V, Cannata G, Testa A et al.. Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Cancer 1994;74:1945–1952.

  • 58

    Mantovani A, Maccio L, Curreli L et al.. Comparison of the effectiveness of three 5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by highly emetogenic chemotherapy (high-dose cisplatin) for the treatment of primary head and neck cancer. Proc Am Soc Clin Oncol 1994;13:428.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 59

    Massidda B, Laconi S, Foddi MR et al.. Prevention of non-cisplatin induced emesis: role of the antagonists of 5-HT receptors. Ann Oncol 1994;5:S204.

  • 60

    Noble A, Bremer K, Goedhals L et al.. A double-blind, randomised, crossover comparison of granisetron and ondansetron in 5-day fractionated chemotherapy: assessment of efficacy, safety and patient preference. Eur J Cancer 1994;30:1083–1088.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 61

    Ruff P, Paska W, Goedhals L et al.. Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicentre double-blind, randomised, parallel-group study. Oncology 1994;51:113–118.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 62

    Italian Group for Antiemetic Research. Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. Ann Oncol 1995;6:805–810.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 63

    Marty M, Kleisbauer JP, Fournel P et al.. Is navoban (tropisetron) as effective as zofran (ondansetron) in cisplatin-induced emesis? Anti-Cancer Drugs 1995;6(Suppl 1):S15–21.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 64

    Navari R, Gandara D, Hesketh P et al.. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. J Clin Oncol 1995;13:1242–1248.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 65

    Stewart A, McQuade B, Cronje JDE et al.. Ondansetron compared with granisetron in the prophylaxis of cyclophosphamide-induced emesis in outpatients: a multi-centre, double-blind, double dummy, randomised, parallel-group study. Oncology 1995;52:202–210.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 66

    Audhuy B, Cappelaere P, Martin M et al.. A double-blind, randomised comparison of the antiemetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy. Eur J Cancer 1996;32A:807–813.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 67

    Fauser AA, Duclos B, Chemaissani A et al.. Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondaneston for the prevention of amesis after moderately emetogenic chemotherapy. European Dolasetron Comparative Study Group. Eur J Cancer 1996;32A:1523–1529.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 68

    Hesketh PJ, Navari R, Grote T et al.. Double-blind, randomised comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. J Clin Oncol 1996;14:2242–2249.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 69

    Leonardi V, Iannitto E, Meli M, Palmeri S. Ondansetron vs granisetron in the control of chemotherapy-induced acute emesis: a multicenter randomized trial. Oncology Rep 1996;3:919–923.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 70

    Lofters WS, Pater JL, Zee B et al.. Phase III double-blind comparison of dolasetron mesylate and ondansetron, and evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy. J Clin Oncol 1997;15:2966–2973.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 71

    Jordan K, Hinke A, Grothey A et al.. A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis. Support Care Cancer 2007;15:1023–1033.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 72

    Huang JQ, Zheng GF, Deuson R et al.. Do 5-hydroxytryptamine3 receptor antagonists (5-HT3) improve the antiemetic effect of dexamethasone for preventing delayed chemotherapy-induced nausea and vomiting (CINV)? A meta-analysis of randomized controlled trials [Abstract]. J Clin Oncol 2004;22:Abstract 6037.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 73

    Chawla SP, Grunberg SM, Gralla RJ et al.. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer 2003;97:2290–2300.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 74

    Hesketh PJ, Grunberg SM, Gralla RJ et al.. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin—the Aprepitant Protocol 052 Study Group. J Clin Oncol 2003;21:4112–4119.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 75

    de Wit R, Herrstedt J, Rapoport B et al.. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials. Eur J Cancer 2004;40:403–410.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 76

    Warr DG, Eisenberg P, Hesketh PJ et al.. Effect of aprepitant for the prevention of nausea and vomiting after one cycle of moderately emetogenic chemotherapy: a randomized double-blind trial in 866 patients [Abstract]. J Clin Oncol 2004;22:Abstract 8007.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 77

    Warr DG, Hesketh PJ, Gralla RJ et al.. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 2005;23:2822–2830.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 78

    Gralla RJ, Warr DG, Carides AD et al.. Effect of aprepitant on antiemetic protection in patients receiving moderately emetogenic chemotherapy plus high-dose cisplatin: analysis of combined data from 2 phase III randomized clinical trials [abstract]. J Clin Oncol 2004;22:Abstract 8137.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 79

    Tremont-Lukats IW, González-Barboteo J, Bruera E et al.. Meta-analysis of neurokinin-1 receptor antagonists (NK-1 RA) for chemotherapy-induced nausea and vomiting (CINV) [Abstract]. J Clin Oncol 2004;22:Abstract 8047.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 80

    Grote T, Hajdenberg J, Cartmell A et al.. Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant. J Support Oncol 2006;4:403–408.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 81

    Shadle CR, Lee Y, Majumdar AK et al.. Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity. J Clin Pharmacol 2004;44:215–223.

  • 82

    Emend [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; 2003. Available at: http://www.fda.gov/cder/foi/label/2008/021549s015lbl.pdf. Accessed April 7, 2009.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 83

    Wampler G. The pharmacology and clinical effectiveness of phenothiazines and related drugs for managing chemotherapy-induced emesis. Drugs 1983;25:31–51.

  • 84

    Gralla RJ, Braun TJ, Itri LM et al.. Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med 1981;305:905–909.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 85

    Gralla RJ, Tyson LB, Borden LA et al.. Antiemetic therapy: a review of recent studies and a report of a random assignment trial comparing metoclopramide with delta-9-tetrahydrocannabinol. Cancer Treat Rep 1984;68:163–172.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 86

    Bakowski MT. Advances in anti-emetic therapy. Cancer Treat Rev 1984;11:237–256.

  • 87

    Grossman B, Lessen LS, Cohen P. Droperidol prevents nausea and vomiting from cisplatinum (letter). N Engl J Med 1979;301:7.

  • 88

    Aapro MS, Alberts DS. High dose dexamethasone for prevention of cisplatinum-induced vomiting. Cancer Chemother Pharmacol 1981;7:11–14.

  • 89

    Aapro MS, Plezia PM, Alberts DS et al.. Double-blind crossover study of the antiemetic efficacy of high-dose dexamethasone versus high-dose metoclopramide. J Clin Oncol 1984;2:466–471.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 90

    Cassileth PA, Lusk EJ, Torri S et al.. Antiemetic efficacy of dexamethasone therapy in patients receiving chemotherapy. Arch Intern Med 1983;143:1347–1349.

  • 91

    Kris MG, Gralla RJ, Clark RA et al.. Consecutive dose-finding trials adding lorazepam to the combination of metoclopramide plus dexamethasone: Improved subjective effectiveness over the combination of diphenhydramine plus metoclopramide plus dexamethasone. Cancer Treat Rep 1985;69:1257–1262.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 92

    Kris MG, Gralla RJ, Clark RA et al.. Antiemetic control and prevention of side effects of anticancer therapy with lorazepam or diphenhydramine when used in conjunction with metoclopramide plus dexamethasone: a double-blind, randomized trial. Cancer 1987;69:1353–1357.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 93

    Herman TS, Einhorn LH, Jones SE. Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. N Engl J Med 1979;200:1295–1297.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 94

    Steele N, Gralla RJ, Braun DW et al.. Double-blind comparison of the antiemetic effects of nabilone and prochlorperazine on chemotherapy-induced emesis. Cancer Treat Rep 1980;64:219–224.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 95

    Navari RM, Einhorn LH, Loehrer PJ et al.. A phase II trial of olanzapine for the prevention of chemotherapy induced nausea and vomiting (CINV) [Abstract]. J Clin Oncol 2004;22:Abstract 8046.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 96

    Navari RM, Einhorn LH, Passik SD et al.. A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study. Support Care Cancer 2005;13:529–534.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 97

    Srivastava M, Brito-Dellan N, Davis MP et al.. Olanzapine as an antiemetic in refractory nausea and vomiting in advanced cancer. J Pain Symptom Manage 2003;25:578–582.

  • 98

    Passik SD, Navari RM, Jung SH et al.. A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study. Cancer Invest 2004;22:383–388.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 99

    Passik SD, Kirsh KL, Theobald DE et al.. A retrospective chart review of the use of olanzapine for the prevention of delayed emesis in cancer patients. J Pain Symptom Manage 2003;25:485–488.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 100

    Passik SD, Lundberg J, Kirsh KL et al.. A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain. J Pain Symptom Manage 2002;23:526–532.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 101

    Morita T, Tei Y, Shishido H et al.. Olanzapine-induced delirium in a terminally ill cancer patient. J Pain Symptom Manage 2004;28:102–103.

  • 102

    Saito M, Aogi K, Sekine I et al.. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 2009;10:115–124.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 103

    Geling O, Eichler H-G. Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol 2005;23:1289–1294.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 104

    Massa E, Astara G, Madeddu C et al.. Palonosetron plus dexamethasone effectively prevents acute and delayed chemotherapy-induced nausea and vomiting following highly or moderately emetogenic chemotherapy in pre-treated patients who have failed to respond to a previous antiemetic treatment: comparison between elderly and non-elderly patient response. Crit Rev Oncol Hematol 2009;70:83–91.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 105

    Franzen L, Nyman J, Hagberg H et al.. A randomized placebo-controlled study with ondansetron in patients undergoing fractionated radiotherapy. Ann Oncol 1996;7:587–592.

  • 106

    Wong RK, Paul N, Ding K et al.. 5-hydroxytryptamine-3 receptor antagonist with or without short-course dexamethasone in the prophylaxis of radiation induced emesis: a placebo-controlled randomized trial of the National Cancer Institute of Canada Clinical Trials Group (SC19). J Clin Oncol 2006;24:3458–3464.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 107

    Belkacemi Y, Ozsahim M, Pene F et al.. Total body irradiation prior to bone marrow transplantation: efficacy and safety of granisetron in the prophylaxis and control of radiation-induced emesis. Int J Radiation Oncol Biol Phys 1996;36:77–82.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 108

    Okamoto S, Takahashi S, Tanosaki R et al.. Granisetron in the prevention of vomiting induced conditioning for stem cell transplantation: a prospective randomized study. Bone Marrow Transplant 1996;17:679–683.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 109

    Ezzo J, Vickers A, Richardson MA et al.. Acupuncture-point stimulation for chemotherapy-induced nausea and vomiting. J Clin Oncol 2005;23:7188–7198.

  • 110

    Morrow GR, Morrell C. Behavioral treatment for the anticipating nausea and vomiting induced by cancer chemotherapy. N Engl J Med 1982;307:1476–1480.

  • 111

    Redd WH, Andrykowski MA. Behavioral intervention in cancer treatment: controlling aversion reactions to chemotherapy. J Consult Clin Psychol 1982;50:1018–1029.

  • 112

    Razavi D, Delvaux N, Farvacques C et al.. Prevention of adjustment disorders and anticipatory nausea secondary to adjuvant chemotherapy: a double-blind, placebo-controlled study of assessing the usefulness of alprazolam. J Clin Oncol 1993;11:1384–1390.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 113

    Physicians’ Desk Reference, 58th ed. Montvale, NJ: Thomson PDR; 2004. Available at http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=5816#nlm34068-7. Accessed April 7, 2009.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 114

    Ellebaek E, Herrstedt J. Optimizing antiemetic therapy in multiple-day and multiple cycles of chemotherapy. Curr Opin Support Palliat Care 2008;2:28–34.

  • 115

    Einhorn LH, Rapoport B, Koeller J et al.. Antiemetic therapy for multiple-day chemotherapy and high-dose chemotherapy with stem cell transplant: review and consensus statement. Support Care Cancer 2005;13:112–116.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 116

    Navari RM. Prevention of emesis from multiple-day and high-dose chemotherapy regimens. J Natl Compr Canc Netw 2007;5:51–59.

  • 117

    Herrstedt J, Sigsgaard TC, Nielsen HA et al.. Randomized, double-blind trial comparing the antiemetic effect of tropisetron plus metopimazine with tropisetron plus placebo in patients receiving multiple cycles of multiple-day cisplatin-based chemotherapy. Support Care Cancer 2007;15:417–426.

    • PubMed
    • Search Google Scholar
    • Export Citation
Copyright:
Copyright © 2009 by the National Comprehensive Cancer Network 2009
Page Numbers:
24
Article Category:
Research Article
Print Publication Date:
01 May 2009
Online Publication Date:
May 2009
Keywords:
NCCN Clinical Practice Guidelines; antiemesis; nausea and vomiting; chemotherapy-induced; 5-HT3–receptor antagonists; NK-1–receptor antagonists

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 2591 981 155
PDF Downloads 627 154 14
EPUB Downloads 0 0 0